Trials / Terminated
TerminatedNCT06790303
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2
A Phase II, Randomized, Open-label Platform Trial Utilizing a Master Protocol to Study Novel Regimens Versus Standard of Care Treatment in NSCLC Participants
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 8 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess the clinical activity of novel regimen (Feladilimab plus Ipilimumab) in participants with NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Feladilimab | Feladilimab will be administered. |
| DRUG | Ipilimumab | Ipilimumab will be administered |
Timeline
- Start date
- 2021-03-04
- Primary completion
- 2021-09-23
- Completion
- 2021-09-23
- First posted
- 2025-01-24
- Last updated
- 2025-06-04
- Results posted
- 2025-06-04
Locations
3 sites across 3 countries: United States, Canada, France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06790303. Inclusion in this directory is not an endorsement.